Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Leads Biolabs CoFRA:0DX -3.38%19 Debt-to-EBITDA is -21.89 as of Dec. 2025. GuruFocus rates FRA:0DX with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 314 Biotechnology companies, Nanjing Leads Biolabs Co ranks worse than 318471.02% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nanjing Leads Biolabs Co's Debt-to-EBITDA or its related term are showing as below:
FRA:0DX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.69 Med: -0.99 Max: -0.2
Current: -1.69
During the past 3 years, the highest Debt-to-EBITDA Ratio of Nanjing Leads Biolabs Co was -0.20. The lowest was -1.69. And the median was -0.99.
FRA:0DX's Debt-to-EBITDA is ranked worse than 100% of 314
companies
in the Biotechnology industry
Industry Median: 1.41
vs FRA:0DX: -1.69
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nanjing Leads Biolabs Co Debt-to-EBITDA Related Terms
Nanjing Leads Biolabs Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co Debt-to-EBITDA Chart
Nanjing Leads Biolabs Co Annual Data
Trend
Dec23
Dec24
Dec25
Debt-to-EBITDA
-0.20
-0.99
-1.68
Nanjing Leads Biolabs Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Debt-to-EBITDA
N/A
0.00
-1.43
-0.93
-21.89
FRA:0DX vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Nanjing Leads Biolabs Co (FRA:0DX) has a Debt-to-EBITDA of -21.89 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nanjing Leads Biolabs Co. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #999999 out of 314 companies in the Biotechnology industry.
Is Nanjing Leads Biolabs Co's Debt-to-EBITDA too high?
Nanjing Leads Biolabs Co's current Debt-to-EBITDA is -21.89. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #999999 out of 314 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #999999 out of 314 companies for Debt-to-EBITDA. This places Nanjing Leads Biolabs Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.41, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nanjing Leads Biolabs Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Leads Biolabs Co's current Debt-to-EBITDA is -21.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current Debt-to-EBITDA of -21.89. The current Debt-to-EBITDA is -21.89. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current Debt-to-EBITDA is -21.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score
Get the complete analysis for FRA:0DX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0DX has been successfully added to your 
